J 2012

Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?

BAREŠ, Martin, Irena REKTOROVÁ, Robert JECH, Kateřina FARNÍKOVÁ, Jan ROTH et. al.

Základní údaje

Originální název

Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson’s disease?

Autoři

BAREŠ, Martin (203 Česká republika, garant, domácí), Irena REKTOROVÁ (203 Česká republika, domácí), Robert JECH (203 Česká republika), Kateřina FARNÍKOVÁ (203 Česká republika), Jan ROTH (203 Česká republika), Evžen RŮŽIČKA (203 Česká republika), Petr KAŇOVSKÝ (203 Česká republika), Ivan REKTOR (203 Česká republika, domácí), Tomáš PAVLÍK (203 Česká republika, domácí), Leona UHLÍŘOVÁ (203 Česká republika) a Jaroslav VYDLÁK (203 Česká republika)

Vydání

Journal of Neural Transmission, 2012, 0300-9564

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.052

Kód RIV

RIV/00216224:14110/12:00059524

Organizační jednotka

Lékařská fakulta

UT WoS

000300587900010

Klíčová slova anglicky

Wearing-off; Parkinson’s disease; Levodopa; WOQ-9; Epidemiology

Příznaky

Mezinárodní význam
Změněno: 16. 4. 2013 16:34, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson’s disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists’ assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0–2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists’ assessment of wearing-off symptoms and PD patients’ subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.